Japan Intellectual Property Rights: T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME AGAINST PRAME POSITIVE CANCERS

Japan, Jan. 21 -- IMMATICS BIOTECHNOLOGIES GMBH has got intellectual property rights for 'T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME AGAINST PRAME POSITIVE CANCERS.' Other related details are as follows:

Application Number: JP,2023-044130

Category (FI): A61K48/00,A61K31/7088,C12P21/02@Z,C12P21/08,C12N5/0783,C12N5/10,C12N15/12,C12N15/63@Z,C07K14/725,C07K16/30,C12N15/13,A61P35/00,A61K35/76,A61K35/17,A61K38/16,A61K40/11,A61K40/32,A61K40/33,A61K40/42

Stage: Grant (IP right document published.)

Filing Date: March 20, 2023

Publication Date: June 27, 2023

The original document can be viewed at: https://www.j-platpat.inpit.go.jp/p0100

Disclaimer: Curated by HT Syndication.